Stem cell transplantation - Clinical
LINKS TO ABSTRACTS:
Presentation ID p428-1
(S240) PROPHYLACTIC OR PRE-EMPTIVE USE OF TYROSINE KINASE INHIBITORS POST-ALLOGENEIC STEM CELL TRANSPLANTATION IN BCR-ABL POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A SUBANALYSIS OF GITMO PH-POSITIVE ALL STUDY.
Anna Candoni, Udine, Italy
The study authors conclude that the data obtained from this analysis in a homogeneous population of Ph-pos ALL who underwent Allo-SCT while in morphological complete remission, although with the caution of a retrospective study, support the prophylactic use of TKIs post-Allo-SCT as an optimal maintenance strategy, resulting in a higher probability of DFS regardless of the Minimal Residual Disease status pre-Allo-SCT.
Presentation ID p428-2
Miguel-Angel Perales, United States
The study authors conclude that in this high-risk patient population with TA-TMA, there were no safety concerns observed with narsoplimab, and treatment resulted in clinically meaningful improvements in laboratory markers of TMA and in organ function or freedom from transfusion.
Presentation ID p428-3
Gesine Bug, Frankfurt, Germany
The study authors conclude that outcomes in LFS, OS and GRFS did not differ between FluTBI and FT. Relapse was lower while NRM higher with FluTBI which may indicate more intense conditioning.
Presentation ID p428-4
Alicia Rovó, Switzerland
The study authors demonstrate that the comparison of overall -, relapse-free survival and relapse incidence shows significantly worse outcomes in CMML compared to MDS, with no difference in NRM. Age was associated with poorer outcomes in both diseases. Despite these significant differences in survival rates between CMML and MDS, they were not able to identify specific factors other than the diseases themselves. They conclude that poorer survival outcomes in CMML in comparison to MDS appear to be the consequence of the significantly higher rate of post-transplant relapse.
Presentation ID p428-5
Presenter: Kazuaki Kameda, Japan
The study authors showed with their data that allo-HCT for PTCL-NOS and AITL failing first-line therapy can result in comparable survival outcomes despite being with more unfavorable factors compared with auto-HCT. They conclude that patients with relapsed-sensitive and primary-refractory disease may be a good candidate for allo-HCT if a suitable donor is available.